Lupin Pharmaceuticals signs agreement with Exeltis to promote Solosec in US

Indian pharma company Lupin Pharmaceuticals has signed an agreement with Exeltis USA to promote its antimicrobial drug Solosec (secnidazole) in the US market.

Solosec is an approved drug in the US, which is used for treating bacterial vaginosis in adult women and trichomoniasis in adults. Bacterial vaginosis is known to be a common vaginal infection, while trichomoniasis is a non-viral, curable sexually transmitted infection.

Vinita Gupta — CEO of Lupin Pharmaceuticals said: “This partnership will expand the reach of Solosec, allowing more Healthcare Providers to be aware of the benefits of Solosec, and increase access for adult women suffering with bacterial vaginosis and adults with trichomoniasis.”

Exeltis will promote Solosec along with its own existing line of women’s health products, thereby further boosting value to OBGYNs and their patients.

Salustiano Perez — CEO of Exeltis said: “Our team is thrilled to embark on this partnership. The addition of Solosec fits precisely within our current portfolio of products, enhancing our commercial strategy, and offering numerous solutions to our customers and their patients.”